Within the biotech sector, the spinal cord injury (SCI) segment stands out as an enormous market with significant unmet needs. The World Health Organization estimates between 250,000 and 500,000 people around the world suffer an SCI each year. It’s also been estimated that around 291,000 people in the US currently live with an SCI, while the European SCI population is up to 500,000 people.

The global SCI therapeutics market generated $6.7 billion of revenues in 2021, and is expected to grow at 5.1% p.a. between 2021 and 2028. So it’s understandable why investors and the global SCI patient population are particularly focused upon the significant potential exosomes offer new and existing SCI patients. Read on to learn more about NurExone, an Israeli-Canadian exosomes-focused biotech delivering particularly promising results from its non-invasive SCI treatment.

Addressing the unmet need for SCI treatments while doing it in an “off the shelf” in a minimally invasive way

While treating SCIs through surgical intervention is often regarded by doctors as necessary, there are numerous risks and complications which many doctors and patients would understandably prefer to avoid. There’s also an awareness across the market that effective non-invasive SCI treatments should be readily available “off the shelf” because time is of the essence when treating patients shortly after their SCI accidents have occurred. So there’s considerable pent-up demand across the market for non-invasive “off the shelf” SCI treatments.

NurExone (TSXV: NRX) is aiming to address this unmet market need for safe, efficient and convenient SCI treatments. The company is developing an exosome-based biological treatment for SCIs which offers the potential to be a revolutionary “off the shelf” non-invasive product. Exosomes are small bubbles which transport molecules from one cell to another, and the main reason exosome therapy is a potential game-changer in the regenerative medicine world is that it improves the communication channels between cells to stimulate healing. NurExone’s exosome-based SCI treatment is delivered intra-nasally so it’s safe, efficient, and convenient for patients and doctors alike.

Early results reveal significant potential

The preliminary results of NurExone’s SCI treatment have shown significant potential. In a joint study conducted on rats at the Technion, Israel's Institute of Technology, together with the Tel Aviv University, NurExone’s SCI treatment showed spinal cord nerve regeneration following the complete lesion of the spinal cord, and enabled the rats to walk again. Significantly, both motor and sensory improvement was evidenced.

NurExone’s treatment is targeting acute SCIs

These preliminary results confirm NurExone’s potential to address acute and traumatic SCI and Central Nervous System (CNS) indications such as Traumatic Brain Injuries (TBI). Compared with existing acute and traumatic SCI treatments, activating any level of recovery, partial or full, would represent a significant quality of life improvement for most patients. So NurExone is aiming to make a revolutionary difference for the global acute and traumatic SCI patient population.

NurExone’s progress is providing hope for SCI patients & unique opportunity for investors

NurExone’s revolutionary exosome-based drug platform is creating a stir within regenerative medicine circles, and for good reason. The company is aiming to address the SCI market with a treatment which may dramatically improve the quality of life of millions of SCI patients. Preliminary results confirm the company’s potential: NurExone’s motor function recovery experiments on rats show the company’s technology is a potential game-changer for the SCI market. As a result, NurExone stands out as an emerging exosomes leader with a compelling biotechnology portfolio and a strong partnership with one of Israel’s leading universities. NurExone is a biotech stock well-positioned for long-term growth as sectoral leadership as they continue to achieve major milestones.